Eucure (Beijing) Biopharma Co.,Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Advanced Solid Tumors
Relapsed Or Refractory Non-Hodgkin Lymphoma

Interventions: Drug: YH004

First Posted Date: 2022-10-04

Last Posted Date: 2023-09-07

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 38

Registration Number: NCT05564806

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

Phase 2

Completed

Conditions: Mucosal Melanoma

Interventions: Drug: YH003
Drug: Pembrolizumab
Drug: albumin paclitaxel

First Posted Date: 2022-06-15

Last Posted Date: 2025-01-06

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 20

Registration Number: NCT05420324

Locations: 🇨🇳
Cancer Hospital of Fujian, Fuzhou, Fujian, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Cancer Hospital of Zhenzhou, Zhengzhou, Henan, China

and more 9 locations

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

Phase 2

Withdrawn

Conditions: HCC
NSCLC Stage IIIB
NSCLC Stage IV

Interventions: Drug: YH001 + Toripalimab

First Posted Date: 2022-01-28

Last Posted Date: 2023-03-20

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Registration Number: NCT05212922

Locations: 🇦🇲
Gabrail Cancer Center Research, Canton, Ohio, Armenia
🇨🇳
The Affiliated Tumour Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China

and more 19 locations

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: YH003
Drug: YH001
Drug: Pembrolizumab

First Posted Date: 2022-01-04

Last Posted Date: 2025-01-06

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 5

Registration Number: NCT05176509

Locations: 🇦🇺
Blacktown Cancer and Haematology Centre, Clinical Trials, Block C, Level 3, 18 Blacktown Road, Blacktown, New South Wales, Australia
🇦🇺
"Oncology Clinical Trial Unit St George Private Hospital 1 South Street", Kogarah, New South Wales, Australia
🇦🇺
55 Commercial Rd, Level 2 WBRC, Melbourne, Victoria, Australia

and more 1 locations

A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: YH002+YH001

First Posted Date: 2021-12-27

Last Posted Date: 2025-01-06

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 6

Registration Number: NCT05169697

Locations: 🇦🇺
Orange Health Services, Orange, New South Wales, Australia
🇦🇺
Macquarie University Hospital, Sydney, New South Wales, Australia
🇦🇺
Peninsula and South Eastern Haematology & Oncology Group, Frankston, Victoria, Australia

and more 6 locations

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: YH004

First Posted Date: 2021-09-10

Last Posted Date: 2023-09-07

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 8

Registration Number: NCT05040932

Locations: 🇦🇺
Westmead Hospital, Sydney, Australia
🇦🇺
Cabrini Health Limited, Malvern East, Australia
🇦🇺
Southside Cancer Care Centre, School of Medicine, University of Wollongong, Wollongong, Australia

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

Phase 2

Completed

Conditions: Melanoma
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: YH003
Drug: Toripalimab
Drug: Nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2021-09-02

Last Posted Date: 2025-01-06

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 40

Registration Number: NCT05031494

Locations: 🇺🇸
Ichan School of Medicine at Mount Sinai, New York, New York, United States
🇦🇺
Epworth Medical Centre, Richmond, Victoria, Australia

A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: YH003

First Posted Date: 2021-08-24

Last Posted Date: 2023-11-18

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 10

Registration Number: NCT05017623

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: YH001

First Posted Date: 2021-01-07

Last Posted Date: 2022-12-12

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 17

Registration Number: NCT04699929

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳
West China Hospital,Sichuan University, Chengdu, Sichuan, China

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: YH003
Drug: Toripalimab
Drug: Nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2020-07-22

Last Posted Date: 2022-12-12

Lead Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Target Recruit Count: 26

Registration Number: NCT04481009

Locations: 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy